Join Growin Stock Community!

Amarin corporation plcAMRN.US Overview

US StockHealthcare
(No presentation for AMRN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AMRN AI Insights

AMRN Overall Performance

AMRN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AMRN Recent Performance

-0.43%

Amarin corporation plc

0.05%

Avg of Sector

-0.31%

S&P500

AMRN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AMRN Key Information

AMRN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AMRN Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Price of AMRN

AMRN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AMRN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.34
PB Ratio
0.64
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
65.74%
Net Margin
-21.10%
Revenue Growth (YoY)
-19.57%
Profit Growth (YoY)
48.52%
3-Year Revenue Growth
-40.06%
3-Year Profit Growth
-29.31%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.34
PB Ratio
0.64
Price-to-FCF
-
Gross Margin
65.74%
Net Margin
-21.10%
Revenue Growth (YoY)
-19.57%
Profit Growth (YoY)
48.52%
3-Year Revenue Growth
-40.06%
3-Year Profit Growth
-29.31%
  • When is AMRN's latest earnings report released?

    The most recent financial report for Amarin corporation plc (AMRN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AMRN's short-term business performance and financial health. For the latest updates on AMRN's earnings releases, visit this page regularly.

  • What is the operating profit of AMRN?

    According to the latest financial report, Amarin corporation plc (AMRN) reported an Operating Profit of 20.5M with an Operating Margin of 105.45% this period, representing a growth of 139.02% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AMRN's revenue growth?

    In the latest financial report, Amarin corporation plc (AMRN) announced revenue of 19.44M, with a Year-Over-Year growth rate of -68.8%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does AMRN have?

    At the end of the period, Amarin corporation plc (AMRN) held Total Cash and Cash Equivalents of 134.86M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AMRN go with three margins increasing?

    In the latest report, Amarin corporation plc (AMRN) did not achieve the “three margins increasing” benchmark, with a gross margin of 119.2%%, operating margin of 105.45%%, and net margin of -6.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AMRN's profit trajectory and future growth potential.

  • Is AMRN's EPS continuing to grow?

    According to the past four quarterly reports, Amarin corporation plc (AMRN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AMRN?

    Amarin corporation plc (AMRN)'s Free Cash Flow (FCF) for the period is 8.55M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 164.24% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AMRN?

    The latest valuation data shows Amarin corporation plc (AMRN) has a Price-To-Earnings (PE) ratio of -1,186.14 and a Price/Earnings-To-Growth (PEG) ratio of 11.96. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.